 SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 GLOBE NEWSWIRE -- Lyell Immunopharma, Inc. Nasdaq: LYEL, a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that five abstracts highlighting preclinical data on its product candidates and new genetic and epigenetic reprogramming technologies were accepted for presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer SITC taking place in Boston, Nov. 8 Nov. 12, 2022. The new preclinical data includes an abstract describing the effects of c-Jun overexpression in combination with NR4A3 gene knockout to enhance the functional activity of ROR1 CAR T cells. The combination of these two genetic reprogramming technologies is being incorporated in Lyells new product candidate, LYL119, a second generation investigational ROR1 targeting CAR T-cell therapy. 